Stockholm Stock Exchange Ends Slightly Down Amid Mixed Corporate News

On August 5, 2026, the Stockholm Stock Exchange (Stockholmsbörsen) closed just slightly down by 0.1%, despite opening the day positively. The broad OMXS 30 index experienced minor declines influenced by varied movements across key companies.

Astra Zeneca's shares rebounded strongly, rising 2.3%, after Reuters denied earlier speculations of a merger with Bristol Myers Squibb. This clarification came following a steep drop earlier in the week caused by the Financial Times' report about possible merger discussions. Similarly, mining company Boliden saw its stock climb by 2.5% on the day.

In contrast, telecommunications firm Tele2 faced a drop of 2.7%, and financial heavyweight Nordea's shares fell 2.3%. The oil market also showed signs of softness, with North Sea oil prices falling to slightly over $79 per barrel.

Meanwhile, Novo Nordisk reported second-quarter results that exceeded expectations, with adjusted sales rising 7% year-on-year to 78.5 billion Danish kroner and adjusted operating profit up 11% to 33.4 billion kroner, beating forecasts significantly. The company attributed improved forecasts to strong demand for its weight loss drug Wegovy, recently approved in Europe. Despite these positive fundamentals, Novo Nordisk's shares fell 4% on the Copenhagen stock exchange.

Market analyst Johan Unnerus from SB1 highlighted Novo Nordisk’s strong performance in diabetes treatments, particularly with Ozempic, but noted competition from Eli Lilly's Mounjaro is intensifying in the obesity and diabetes markets. The weight loss medication market remains nascent in Europe, with substantial out-of-pocket costs for patients as companies seek subsidies.

The mixed stock performances reveal evolving investor sentiments responding to latest corporate news and financial results, shaping cautious optimism across Swedish equities and related markets.